A Study Using Fractional Carbon Dioxide and Long Pulsed Neodymium-yttrium Aluminum Garnet Lasers in Treatment of Keloids
NCT ID: NCT03460431
Last Updated: 2018-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2014-07-01
2017-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Photobiomodulation and the Intralesional Administration of Corticoid in the Keloid Surgery.
NCT04824612
Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids
NCT02996097
Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study.
NCT06230146
Safety and Efficacy of Infrared Diode Laser on Improvement of Scar and Prevention of Recurrence of Excised Keloid
NCT01158196
Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of Keloid
NCT06431360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methodology
Patients:
\- Thirty patients with keloid scar(s) were included in the study
\- Every patient was subjected to the following:
1. Complete history taking: History of disease onset, course and duration, family history as well as history of any systemic or dermatological disease interfering with the eligibility of participation in the study.
Thirty patients were included in the study which is a clinical comparative study comparing the effectiveness of fractional CO2, long pulsed Nd YAG and their combination in collagen remodeling in keloid clinically in all the included patients and biochemically and immunohistochemically fifteen patient
2. Full clinical examination:
* General examination to determine any systemic or dermatological disease that might preclude the patient from participation in the study such as collagen disease.
* Local examination to determine Fitzpatrick skin color of the patient and the site and extent of the scar to be treated.
Methods:
\- Cases with multiple keloid scars three lesions 2 to 3 cm apart from each other were selected and labeled. The first one (lesion A) was treated using fractional CO2 laser 10,600 nm, the second (lesion B) long pulsed Nd YAG laser 1064 nm, while the last (lesion C) combined fractional CO2 followed by Nd YAG lasers after half an hour were used
\- patients who had a large sized lesion, the lesion was divided into three equal parts 2 to 3 cm apart from each other, they were labeled as areas A, B and C then subjected to the same treatment modalities as mentioned in case of multiple lesions.
* Patients received 4 treatment sessions 4 to 8 weeks apart. Laser modalities and parameters
* Topical anesthesia (lidocaine 2.5% and prilocaine 2.5%) was applied to the working area 30 to 60 minutes before the sessions, washed off and properly dried before the procedure.
* Ablative fractional 10,600 nm carbon dioxide laser (DEKA smartxide DOT, Italy) and long pulsed Nd-YAG (DEKA synchro FT) were used in the treatment sessions with the following parameters Fractional CO2 Stacking: 5, Power: 20 Watt, Dwell time: 1000 micro second, Spacing : 800 micro meter fluence: 40 j/cm2 Pulse duration: 0.3 milli second Spot size: 5 mm Passes: 3.
Assessment Assessment was done before treatment every session and one months after the final laser treatment. Clinical assessment was done for all patients while histopathological and biochemical assessment were done only in 15 patients.
A. Clinical evaluation Clinical assessment was fulfilled via calculating the scores of both the Vancouver Scar Scale; and the Patient and Observer Scar Assessment Scale. Patients were assessed every session, any side effects were reported, e.g pain, swelling, infection, hyper pigmentation or hypo pigmentation.
B. Histopathological and biochemical evaluation
Fifteen patients were randomly selected and subjected to the pre and post treatment biopsies :
* Pretreatment biopsy:
Three mm punch skin biopsy was taken from the keloid (any lesion A, B, or C) before starting treatment sessions ●Post treatment biopsies: Each lesion (A, B, C) was biopsied separately (3 mm punch biopsy), one month after last treatment session.
Biopsies of controls ●parts of excess skin from 12 patients undergoing abdominoplasty were used as controls for levels of TGFβ1 and TGFβ3.
Procedure
\- Biopsies were fixed in 10 % neutral buffered formalin, and then embedded in paraffin blocks. Sections were prepared for routine staining by H\&E. Other sections were prepared for histochemical staining of collagen fibres using Masson's trichrome stain and elastic fibres using orcein stain
\- All sections were examined using a Zeiss, Primo star light microscope (Zeiss, Germany). The microscope has an integrated camera by which photomicrographs depicting the various histopathological and histochemical findings were obtained. All photomicrographs presented in the thesis are according to their original magnification.
• Evaluation of elastic fibres in orcein stained sections:
Orcein stained sections were graded according to the grading criteria proved by Ozog et al. in 2013 for the appearance of the dermal elastic tissue as follows:
0 normal
1. short fragmented elastic fibres
2. intermediate between 1 and 3
3. fibrillar elastic fibres, parallel to epidermis
4. intermediate between 3 and 5
5. absent or nearly absent.
Image analyzer evaluation (morphometric study):
The area percent of collagen and elastic fibres were quantitatively evaluated in Masson's trichrome and orcein stained sections respectively at magnification X100 in 5 non overlapping fields for all patients. Image analysis was done using Leica Qwin 500C image analyzer computer system (England) present in the Histology Department, Faculty of Medicine, Cairo University .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fractional CO2 laser 10,600nm
fractional CO2 laser 10,600nm one session every month for 4 months
fractional CO2 laser 10,600nm
fractional CO2 laser 10,600nm session, every month for 4 months
Nd YAG laser 1064nm
Nd YAG laser 1064nm
Nd YAG laser1064 nm
Nd YAG laser1064 nm laser session, every month for 4 months
combined two laser types
combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
fractional CO2 laser 10,600nm
fractional CO2 laser 10,600nm session, every month for 4 months
Nd YAG laser1064 nm
Nd YAG laser1064 nm laser session, every month for 4 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fractional CO2 laser 10,600nm
fractional CO2 laser 10,600nm session, every month for 4 months
Nd YAG laser1064 nm
Nd YAG laser1064 nm laser session, every month for 4 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No limitations regarding sex of the patients.
* Patients with three or more lesions 2 to 3 cm apart or patients having a large sized lesion.
Exclusion Criteria
* Patients with active skin infections e.g. herpes or autoimmune disease.
* Patients with previous history of adverse outcome related to laser therapy.
* Recent use of Isotretinoin (within 6 months prior to the procedure).
* Patients with known allergies to lidocaine.
* Smoking, pregnancy
* Patients with unrealistic expectations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Foad Mohamed
specialist of dermatology.students hospital. Cairo university
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shereen O Tawfik, MD
Role: STUDY_DIRECTOR
professor of Dermatology.faculty of medicine. Cairo university
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3060114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.